Download these slides from an expert-led symposium reviewing the latest advances in targeted therapy for HR-positive/HER2-negative early-stage breast cancer.
Download these slides from an expert-led symposium for the most recent data on the selection and sequencing of targeted therapy for HR-positive/HER2-negative metastatic breast cancer.
Download these slides from an expert-led symposium on the practical management of adverse events with targeted therapy for HR-positive/HER2-negative breast cancer and strategies to optimize adherence.
In this on-demand webcast from a live symposium, experts Komal Jhaveri, MD, FACP; Erica L. Mayer, MD, MPH; and Laura M. Spring, MD, discuss how they apply current clinical evidence to develop personalized treatment plans for HR-positive/HER2-negative early and advanced breast cancer, including the use of current and emerging targeted therapies and strategies to promote patient adherence.
Experts discuss key updates in hormone receptor–positive breast cancer, including recent data presented at ASCO 2022.